Back to Search
Start Over
Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC.
- Source :
-
Cancer Biomarkers . 2012, Vol. 10 Issue 6, p287-298. 12p. 4 Charts, 3 Graphs. - Publication Year :
- 2012
-
Abstract
- We investigated the relationship between plasma protein biomarker concentrations and clinical outcomes in 52 patients with relapsed/refractory advanced non-small cell lung cancer (NSCLC) treated with 400~mg bid sorafenib in a phase II trial. Blood samples were collected at baseline, on day 15 of cycle 1 (C1D15), and on day 1 of cycle 3 (C3D1), and plasma concentrations of total VEGF, VEGF-165, soluble (s) VEGFR-2, PDGF-BB, sPDGFR-β, sEGFR, sHER-2, uPA, PAI-1, uPAR, TIMP-1, and circulating Ras p21 were assayed by ELISA. Elevated baseline VEGF, VEGF-165, PDGF-BB, Ras p21, and TIMP-1 concentrations were associated with poorer patient outcomes (shorter overall survival [OS] and/or progression-free survival [PFS]). During treatment, the mean concentrations of sVEGFR-2, PDGF-BB, sPDGFR-β, TIMP-1, uPAR, and PAI-1 decreased, while the mean sEGFR concentration increased. Increases in VEGF, VEGF-165, PDGF-BB, and TIMP-1 during treatment were associated with better outcomes (longer OS and/or PFS), whereas increases in plasma Ras p21 during treatment were associated with shorter PFS. The associations between baseline concentrations and/or pharmacodynamic changes in plasma proteins and clinical outcomes in NSCLC patients treated with sorafenib suggest that these biomarkers may have a prognostic role and/or predict the efficacy of sorafenib in patients with NSCLC. [ABSTRACT FROM AUTHOR]
- Subjects :
- *BIOMARKERS
*LUNG cancer
*PROTEINS
*CLINICAL trials
*CANCER patients
Subjects
Details
- Language :
- English
- ISSN :
- 15740153
- Volume :
- 10
- Issue :
- 6
- Database :
- Academic Search Index
- Journal :
- Cancer Biomarkers
- Publication Type :
- Academic Journal
- Accession number :
- 77873906
- Full Text :
- https://doi.org/10.3233/CBM-2012-0253